AU2013235535B2 - Compounds and methods for treating aberrant adrenocortical cell disorders - Google Patents

Compounds and methods for treating aberrant adrenocortical cell disorders Download PDF

Info

Publication number
AU2013235535B2
AU2013235535B2 AU2013235535A AU2013235535A AU2013235535B2 AU 2013235535 B2 AU2013235535 B2 AU 2013235535B2 AU 2013235535 A AU2013235535 A AU 2013235535A AU 2013235535 A AU2013235535 A AU 2013235535A AU 2013235535 B2 AU2013235535 B2 AU 2013235535B2
Authority
AU
Australia
Prior art keywords
atr
patient
phenyl
administering
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013235535A
Other languages
English (en)
Other versions
AU2013235535A1 (en
Inventor
Gary HAMMER
Raili Kerppola
Tom Kerppola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Millendo Therapeutics Inc
Original Assignee
University of Michigan System
Millendo Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System, Millendo Therapeutics Inc filed Critical University of Michigan System
Publication of AU2013235535A1 publication Critical patent/AU2013235535A1/en
Assigned to THE REGENTS OF THE UNIVERSITY OF MICHIGAN, MILLENDO THERAPEUTICS, INC. reassignment THE REGENTS OF THE UNIVERSITY OF MICHIGAN Alteration of Name(s) of Applicant(s) under S113 Assignors: ATTEROCOR, INC., THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Application granted granted Critical
Publication of AU2013235535B2 publication Critical patent/AU2013235535B2/en
Priority to AU2017261632A priority Critical patent/AU2017261632A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2013235535A 2012-03-22 2013-03-13 Compounds and methods for treating aberrant adrenocortical cell disorders Active AU2013235535B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017261632A AU2017261632A1 (en) 2012-03-22 2017-11-17 Compounds and methods for treating aberrant adrenocortical cell disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261614269P 2012-03-22 2012-03-22
US61/614,269 2012-03-22
PCT/US2013/031068 WO2013142214A1 (en) 2012-03-22 2013-03-13 Compounds and methods for treating aberrant adrenocartical cell disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017261632A Division AU2017261632A1 (en) 2012-03-22 2017-11-17 Compounds and methods for treating aberrant adrenocortical cell disorders

Publications (2)

Publication Number Publication Date
AU2013235535A1 AU2013235535A1 (en) 2014-10-09
AU2013235535B2 true AU2013235535B2 (en) 2017-09-21

Family

ID=48014328

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2013235535A Active AU2013235535B2 (en) 2012-03-22 2013-03-13 Compounds and methods for treating aberrant adrenocortical cell disorders
AU2017261632A Abandoned AU2017261632A1 (en) 2012-03-22 2017-11-17 Compounds and methods for treating aberrant adrenocortical cell disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017261632A Abandoned AU2017261632A1 (en) 2012-03-22 2017-11-17 Compounds and methods for treating aberrant adrenocortical cell disorders

Country Status (12)

Country Link
US (5) US9107883B2 (enExample)
EP (1) EP2838523A1 (enExample)
JP (2) JP6234987B2 (enExample)
CN (2) CN104302283B (enExample)
AU (2) AU2013235535B2 (enExample)
BR (1) BR112014023517B1 (enExample)
CA (1) CA2867668A1 (enExample)
HK (1) HK1206607A1 (enExample)
IN (1) IN2014DN08604A (enExample)
MX (1) MX355129B (enExample)
NZ (1) NZ630828A (enExample)
WO (1) WO2013142214A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2748238B2 (ja) 1994-12-20 1998-05-06 新興機械工業株式会社 ばね製造装置の足起こし装置
US9107883B2 (en) * 2012-03-22 2015-08-18 Atterocor, Inc. Compounds and methods for treating aberrant adrenocartical cell disorders
US20150087649A1 (en) * 2013-09-26 2015-03-26 Atterocor, Inc. Treating disorders associated with aberrant adrenocortical cell behavior
CN107205941A (zh) * 2014-09-26 2017-09-26 米伦多治疗公司 N‑(2,6‑二(1‑甲基乙基)苯基)‑n′‑((1‑(4‑(二甲基氨基)苯基)环戊基)甲基)脲盐酸盐的固体药物形式以及涉及其的组合物、方法和试剂盒
WO2016164476A2 (en) * 2015-04-06 2016-10-13 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
US20180200209A1 (en) * 2015-07-10 2018-07-19 Millendo Therapeutics, Inc. Enhanced bioavailability of n-(2,6-bis(1-methylethyl)phenyl)-n'-((1-(4-(dimethylamino)-phenyl)cyclopentyl)methyl)urea hydrochloride
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer
US10231983B1 (en) 2018-08-22 2019-03-19 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US11202787B2 (en) 2018-07-02 2021-12-21 Corcept Therapeutics, Inc. Use of ACTH in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US10780097B2 (en) 2018-07-02 2020-09-22 Corcept Therapeutics, Inc. Use of cortisol in assessment and prophylactic treatment of hypokalemia associated with glucocorticoid receptor modulator treatment of Cushing's syndrome patients
US20220241276A1 (en) * 2019-06-11 2022-08-04 The Regents Of The University Of Michigan Compositions and methods for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
WO2009067397A2 (en) * 2007-11-19 2009-05-28 Ore Pharmaceuticals Inc. Treatment for solid tumors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
US9107883B2 (en) * 2012-03-22 2015-08-18 Atterocor, Inc. Compounds and methods for treating aberrant adrenocartical cell disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070692A2 (en) * 2006-12-06 2008-06-12 Smithkline Beecham Corporation Bicyclic compounds and use as antidiabetics
WO2009067397A2 (en) * 2007-11-19 2009-05-28 Ore Pharmaceuticals Inc. Treatment for solid tumors

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEN DAVID Y T ET AL: "Treatment of adrenocortical carcinoma: contemporary outcomes", CURRENT UROLOGY REPORTS, CURRENT SCIENCE, US, vol. 5, no. 1, 1 February 2004 (2004-02-01), pages 65-72, , ISSN: 1527-2737 *
Dominick et al. Morphogenesis of a zone-specific adrenocortical cytotoxicity in guinea pigs administered PD 132301-2, an inhibitor of acyl-CoA: cholesterol acyltransferase. Toxicologic Pathology, vol. 21, No. 1, 1993 *
VERNETTI L A ET AL, TOXICOLOGY AND APPLIED PHARMACOLOGY, ACADEMIC PRESS, AMSTERDAM, NL, vol. 118, no. 1, 1 January 1993 (1993-01-01), pages 30-38 *

Also Published As

Publication number Publication date
US20160367507A1 (en) 2016-12-22
HK1206607A1 (en) 2016-01-15
CN106236741A (zh) 2016-12-21
US9877937B2 (en) 2018-01-30
AU2017261632A1 (en) 2017-12-07
NZ630828A (en) 2016-10-28
AU2013235535A1 (en) 2014-10-09
US20220160662A1 (en) 2022-05-26
US9107883B2 (en) 2015-08-18
CN104302283B (zh) 2016-08-24
US9446010B2 (en) 2016-09-20
CA2867668A1 (en) 2013-09-26
JP6317016B2 (ja) 2018-04-25
IN2014DN08604A (enExample) 2015-05-22
US20160008302A1 (en) 2016-01-14
JP2017160275A (ja) 2017-09-14
US20130267550A1 (en) 2013-10-10
BR112014023517B1 (pt) 2020-12-01
CN104302283A (zh) 2015-01-21
US20180256524A1 (en) 2018-09-13
EP2838523A1 (en) 2015-02-25
MX355129B (es) 2018-04-06
MX2014011188A (es) 2015-03-06
JP2015510933A (ja) 2015-04-13
JP6234987B2 (ja) 2017-11-22
WO2013142214A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
US20220160662A1 (en) Compounds and methods for treating aberrant adrenocortical cell disorders
TWI289449B (en) Compositions and methods for the treatment of cancer
TWI377062B (en) Pharmaceutical compositions and dosage forms of thalidomide
US20020128228A1 (en) Compositions and methods for the treatment of cancer
US20230310354A1 (en) Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
AU2014332171B2 (en) Formulations of (S)-3-(4-((4-(morpholinomethyl)benzyloxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
CN102908346A (zh) 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮在套细胞淋巴瘤治疗中的用途
US12090147B2 (en) Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
TW201642857A (zh) 以組合療法治療肝細胞癌
HK1230524A (en) Compounds and methods for treating aberrant adrenocartical cell disorders
HK1230524A1 (en) Compounds and methods for treating aberrant adrenocartical cell disorders
US20240216465A1 (en) Method for treating refractory brain tumor
TW202428876A (zh) 治療難治型腦瘤之方法
HK40068523A (en) Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
HK1261967B (en) Cyp26-resistant rar-alpha selective agonists in the treatment of cancer

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ COMPOUNDS AND METHODS FOR TREATING ABERRANT ADRENOCORTICAL CELL DISORDERS

FGA Letters patent sealed or granted (standard patent)